Drug Trial Radar · NCT07288034
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
535
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Oct 8, 2028
Study completion Oct 8, 2028
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD\[L\]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Response and survival rates in advanced stage NSCLC, unlike other cancers, rely on response to first-line therapy. Immunotherapy with PD(L)1-based therapy, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. While immunotherapy has improved survival rate, the prognosis remains poor with most patients receiving chemotherapy after immunotherapy. Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid (DNA) which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. The first part of this trial, studying samples of blood and tissue in the laboratory from patients receiving immunotherapy may help doctors learn more about the effects PD(L)1-based therapy on cells. It may also help doctors understand how well patients respond to treatment and may help develop new individualized treatment strategies. The second part of this trial also tests the effect of second-line immunotherapy, such as tremelimumab and durvalumab or adagrasib and bevacizumab, in treating patients with NSCLC with specific genetic mutations that is growing, spreading or getting worse (progressive). Tremelimumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adagrasib, a type of targeted therapy, may stop the growth of tumor cells by blocking a protein needed for tumor cell growth and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving second-line immunotherapy, tremelimumab and durvalumab or adagrasib with bevacizumab, may be safe, tolerable, and/or effective in treating patients with stage IIIB/IV NSCLC with specific genetic mutations.
Conditions
- Lung Non-Small Cell Carcinoma
- Stage IIIB Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
Interventions
AdagrasibDrug
Given PO
Anti-PD-L1 Monoclonal AntibodyBiological
Given PD-L1-based immunotherapy
Anti-PD1 Monoclonal AntibodyBiological
Given PD1-based immunotherapy
BevacizumabBiological
Given IV
Biopsy ProcedureProcedure
Undergo tumor biopsy
Biospecimen CollectionProcedure
Undergo blood, CSF, ascites and pleural fluid sample collection
ChemotherapyDrug
Given chemotherapy
Computed TomographyProcedure
Undergo CT
DurvalumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo PET
MonitoringOther
Undergo monitoring
Positron Emission TomographyProcedure
Undergo PET
SurveillanceBehavioral
Undergo close surveillance
TremelimumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) during first-line treatment (Part I)Time frame: From the start of randomization to disease progression or death from any cause, whichever occurs first, assessed up to 3 years
- PFS by arm for second-line treatment (Part II)Time frame: From the start of treatment to disease progression or death from any cause, whichever occurs first, assessed up to 3 years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
CTCA at Western Regional Medical Center
Goodyear, Arizona · Recruiting
City of Hope Corona
Corona, California · Recruiting
City of Hope Medical Center
Duarte, California · Recruiting
City of Hope Seacliff
Huntington Beach, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Recruiting
City of Hope at Long Beach Elm
Long Beach, California · Recruiting
City of Hope at Newport Beach Fashion Island
Newport Beach, California · Recruiting
City of Hope South Pasadena
South Pasadena, California · Recruiting
City of Hope South Bay
Torrance, California · Recruiting
City of Hope Upland
Upland, California · Recruiting
City of Hope Atlanta Cancer Center
Newnan, Georgia · Recruiting
City of Hope at Chicago
Zion, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.